Generic Name: iothalamate
Applies to iothalamate: injectable solution
Common (1% to 10%): Pruritus, urticarial, face edemaUncommon (0.1% to 1%): Erythema, rashRare (less than 0.1%): Angioedema, diaphoresisFrequency not reported: Ecchymosis and tissue necrosis[Ref]
Common (1% to 10%): Nausea, vomitingRare (0.01% to 0.1%): Diarrhea, dry mouth, tongue edemaVery rare (less than 0.01%): Dysphagia[Ref]
Common (1% to 10%): Anaphylactoid reactionsFrequency not reported: Dermal manifestations (urticaria with or without pruritus, erythema, maculopapular rash); dry mouth, sweating, conjunctival symptoms; facial, peripheral, and angioneurotic edema; symptoms related to the respiratory system include sneezing, nasal stuffiness, coughing, choking, dyspnea, chest tightness and wheezing, which may be initial manifestations of more severe and infrequent reactions including asthmatic attack, laryngospasm and bronchospasm with or without edema, pulmonary edema, apnea and cyanosis[Ref]
Rarely, these allergic-type reactions can progress into anaphylaxis with loss of consciousness and coma and severe cardiovascular disturbances.[Ref]
Common (1% to 10%): RhinitisUncommon (0.1% to 1%): Coughing, dyspneaRare (0.01% to 0.1%): Larynx edemaVery rare (less than 0.01%): Apnea, bronchospasm[Ref]
Uncommon (0.1% to 1%): HypotensionRare (0.01% to 0.1%): Thrombophlebitis, tachycardia, ventricular fibrillation, pallor, vasodilation, cyanosisVery rare (less than 0.01%): Disseminated intravascular coagulation resulting in death; arrhythmia; bradycardia; cardiac arrest, circulatory failure; abnormal ECG; heart block; phlebitisFrequency not reported: Generalized vasodilation, flushing and venospasm; occasionally thrombosis; severe cardiovascular responses include rare cases of hypotensive shock, coronary insufficiency, cardiac arrhythmia, fibrillation and arrest; extravasation with burning pain; hematomas; vascular constriction due to injection rate; thrombosis[Ref]
These severe reactions are usually reversible with prompt and appropriate management; however, fatalities have occurred.[Ref]
Uncommon (0.1% to 1%): Thyroid function tests indicative of hypothyroidism or transient thyroid suppression in adults and pediatric patients (including infants)[Ref]
Uncommon (0.1% to 1%): Periorbital edemaRare (0.01% to 0.1%): ConjunctivitisVery rare (less than 0.01%): Vision disorders[Ref]
Rare (less than 0.1%): Injection side reaction[Ref]
Rare (0.01% to 0.1%): Dizziness; paraesthesia; taste perversionVery rare (less than 0.01%): Agitation, coma, convulsions, dyskinesia, paralysis, tremor, somnolenceFrequency not reported: Aphasia; syncope, paresis; paralysis resulting from spinal cord injury and pathology associated with syndrome of transverse myelitis; visual field losses which are usually transient but may be permanent; coma and death; headache, trembling, shaking, numbness[Ref]
Very rare (less than 0.01%): Urinary incontinence[Ref]
Very rare (less than 0.01%): Thirst[Ref]
Very rare (less than 0.01%): Involuntary muscle contractions, myalgia, leg painFrequency not reported: Spasm[Ref]
Very common (10% or more): Hot flushes, painRare (0.01% to 0.1%): MalaiseVery rare (less than 0.01%): Edema, abnormal cryingFrequency not reported: Chills without fever and lightheadedness[Ref]
Very rare (less than 0.01%): Anxiety[Ref]
Very rare (less than 0.01%): Acute renal failure, decrease in renal functionFrequency not reported: Temporary renal shutdown or other nephropathy[Ref]
Frequency not reported: Red blood cell clumping and agglutination, crenation and interference in clot formation[Ref]
1. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc, St. Louis, MO. 
2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum,  Inc. "Australian Product Information." O 0
Not all side effects for Cysto-Conray II may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
